Monitor for next-stage trial initiation (Phase 2/3) and any partnership or regulatory feedback on EP-104GI; the data is supportive but non-pivotal, so near-term stock movement likely limited to sentiment-driven trading.
Price Chart
Executive Summary
Eupraxia Pharmaceuticals announced updated Phase 1b/2a RESOLVE data for EP-104GI in Eosinophilic Esophagitis, showing long response duration, high remission rates, and tolerability. The data is early-stage and non-pivotal, providing incremental positive read-through for the asset's potential but no definitive regulatory or commercial catalyst.
Key Facts
- Updated clinical data from Phase 1b/2a RESOLVE study for EP-104GI in Eosinophilic Esophagitis
- Data highlights long duration of response, high remission rates, and tolerability
- EP-104GI is based on Eupraxia's proprietary Diffusphere technology for local, controlled drug delivery
Financial Impact
No financial figures disclosed; early-stage clinical data with no revenue or cost impact reported
Risk Factors
- Phase 1b/2a data is early-stage and may not translate to pivotal trial success
- No regulatory submission or approval timeline provided
- EoE competitive landscape includes approved therapies (e.g., dupilumab) that may limit commercial opportunity
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3371804 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 6-K | $7.59 | awaiting T+5 | — | $7.08 (−6.72%) |
Oct 15, 2026 12d ago | 6-K | $6.77 $7.59 | ▲ +12.11% | ▲ +13.13% | $7.08 (+4.58%) |
Oct 9, 2026 18d ago | 6-K | $7.46 $6.62 | ▼ −11.26% | ▼ −9.29% | $7.08 (−5.09%) |
Sep 30, 2026 27d ago | 6-K | $9.10 $7.78 | ▼ −14.51% | ▼ −16.42% | $7.08 (−22.20%) |
Sep 30, 2026 27d ago | Press Release | $9.10 $7.78 | ▼ −14.51% | ▼ −16.42% | $7.08 (−22.20%) |
Aug 25, 2026 9w ago | EFFECT | $7.42 $6.34 | ▲ +14.56% | ▲ +14.02% | $7.08 (+4.58%) |
Aug 13, 2026 10w ago | 6-K | $6.67 $6.76 | ▲ +1.35% | ▲ +3.31% | $7.08 (+6.15%) |
Aug 11, 2026 11w ago | Press Release | $6.48 $7.01 | ▲ +8.18% | ▲ +8.62% | $7.08 (+9.26%) |
Jul 15, 2026 14w ago | 6-K | $6.52 $6.42 | ▼ −1.53% | ▼ −0.55% | $7.08 (+8.59%) |
Jun 19, 2026 18w ago | Press Release | $6.64 $6.60 | ▼ −0.60% | ▲ +1.47% | $7.08 (+6.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers